NCT03331393已完成不适用
The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study
Bristol-Myers Squibb4 个研究点 分布在 1 个国家目标入组 265 人开始时间: 2017年3月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 265
- 试验地点
- 4
- 主要终点
- number of patients discontinuing treatment before completing 12 months of therapy
研究概览
简要总结
The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age at enrollment
- •Confirmed diagnosed with RA
- •Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site
排除标准
- •Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
- •Was followed at the site for less than 1 year since biologic treatment initiation
- •Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula
- •Other protocol defined inclusion/exclusion criteria could apply
结局指标
主要结局
number of patients discontinuing treatment before completing 12 months of therapy
时间窗: approximately 1 year
time from treatment initiation to discontinuation
时间窗: approximately 1 year
次要结局
- Joint Erosions(approximately 1 year)
- Erythrocyte Sedimentation Rate(approximately 1 year)
- C-reactive Protein Levels(approximately 1 year)
- Distribution of Healthcare Resource Utilization (HCRU)(approximately 1 year)
- Disease Activity Score(approximately 1 year)
- Health Assessment Questionnaire(approximately 1 year)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Maintenance Trial by Orencia in Rheumatoid ArthritisRheumatoid ArthritisJPRN-UMIN000010286Hokkaido University Hospital150
已完成
不适用
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome Endocrinopathy (ROSE II Trial)JPRN-UMIN000016273Department of Internal Medicine, Faculty of Medicine, University of Tsukuba68
招募中
2 期
Rheumatoid Arthritis with Orencia Trial Toward Sjogren's syndrome endocrinopathy (ROSE Trial)rheumatoid arthritis complicated by sjogren's syndromeJPRN-UMIN000005724Division of Clinical Immunology, Major of Advanced Biochemical Applications, Graduate School of Comprehensive Human Science,University of Tsukuba Takayuki Sumida30
招募中
不适用
Orencia Clinical study in Early rheumatoid Arthritis using New criteria(Efficacy and safety of MTX therapy and Abatacept/MTX combination therapy in early RA patients in daily clinical practice retrospective observation study.)Rheumatoid ArthritisJPRN-UMIN000011019School of Medicine, Keio University75
已完成
不适用
An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid ArthritisRheumatoid Arthritis (RA)NCT04267536AbbVie534